Escitalopram in the treatment of major depressive disorder: A meta-analysis
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the relative antidepressant efficacy of escitalopram and comparator antidepressants. RESEARCH DESIGN AND METHODS: A meta-analysis was performed using studies in major depressive disorder (MDD) comparing escitalopram with active controls, including selective serotonin reuptake inhibitors [SSRIs] (citalopram, fluoxetine, paroxetine, sertraline) and serotonin/noradrenaline reuptake inhibitors [SNRIs] (venlafaxine, duloxetine). Adult patients had to meet DSM-IV criteria for MDD. MAIN OUTCOME MEASURES: The primary outcome measure was the treatment difference in Montgomery-Asberg Depression Rating Scale (MADRS) total score at week 8. Secondary outcome measures were response and remission (MADRS total score < or = 12) rates. RESULTS: Individual patient data (N = 4549) from 16 randomized controlled trials were included in the analyses (escitalopram n = 2272, SSRIs n = 1750, SNRIs n = 527). Escitalopram was significantly more effective than comparators in overall treatment effect, with an estimated mean treatment difference of 1.1 points on the MADRS (p < 0.0001), and in responder (63.7 vs. 58.3%, p < 0.0001) and remitter (53.1 vs. 49.4%, p < 0.0059) analyses. Escitalopram was significantly superior to SSRIs, with an estimated difference in response of 62.1 vs. 58.4% and remission of 51.6 vs. 49.0%. In comparison to SNRIs, the estimated difference in response was 68.3 vs. 59.0% (p = 0.0007) and for remission the difference was 57.8 vs. 50.5% (p = 0.0088). These results were similar for severely depressed patients (baseline MADRS > or = 30). Sensitivity analyses were performed with data from articles reporting Hamilton Rating Scale for Depression (HAMD) scores. The 8-week withdrawal rate due to adverse events was 5.4% for escitalopram and 7.9% for the comparators (p < 0.01). This difference was accounted for by statistically significant higher attrition rates in the SNRI comparisons. This work may be limited by the clinical methodology underlying meta-analytic studies, in particular, the exclusion of trials that fail to meet predetermined criteria for inclusion. CONCLUSIONS: In this meta-analysis, superior efficacy of escitalopram compared to SSRIs and SNRIs was confirmed, although the superiority over SSRIs was largely explained by differences between escitalopram and citalopram.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationSmall sample inference for fixed effects from restricted maximum likelihood
Kenward, M. G., & Roger, J. H. (1997) · Biometrics · doi:10.2307/2533558 · Cited by 4,552
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 1×
“The following inclusion criteria were used to select studies for this meta-analysis: (1) patients were either men or women 18 years old; (2) satisfying DSM-IV criteria for MDD; (3) baseline score 16 on the 17-item Hamilton Rating Scale for Depression (HAMD17) 20 or 18 on the Montgomery–Åsberg Depression Rating Scale (…”
MethodSelf-citationAnderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940 · cited 1×
“The following inclusion criteria were used to select studies for this meta-analysis: (1) patients were either men or women 18 years old; (2) satisfying DSM-IV criteria for MDD; (3) baseline score 16 on the 17-item Hamilton Rating Scale for Depression (HAMD17) 20 or 18 on the Montgomery–Åsberg Depression Rating Scale (…”
MethodPapakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
Self-citationLepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Executive Dysfunction, Heart Disease Burden, and Remission of Geriatric Depression
Alexopoulos, G. S., Kiosses, D. N., Murphy, C., & Heo, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300557 · Cited by 117
Cited by
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“…there is some evidence for superiority of venlafaxine over SSRIs (Bauer et al., 2009; Nemeroff et al., 2008; Weinmann et al., 2008), escitalopram over citalopram, venlafaxine, and duloxetine (Kennedy et al., 2008) and sertraline over fluoxetine and other SSRIs as a class (Cipriani et al., 2008).”
BackgroundKennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Self-citationLam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
“The full methods have been described elsewhere (Kennedy et al., 2009b) but, in summary, relevant English language studies published from January 1, 2000 to December 31, 2008 were identified using computerized searches of electronic databases (PubMed, PsychInfo, Cochrane Register of Clinical…”
MethodSelf-citationA comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
“…efficacy of escitalopram compared with paroxetine and sertraline as well as other SSRIs and SNRIs, though the superiority to other SSRIs was to the largest degree between escitalopram and citalopram (Kennedy et al., 2009), a difference that has been well established (Montgomery et al., 2011).”
BackgroundResultInfluentialSaveanu, R., Etkin, A., Duchemin, A.-M., Goldstein-Piekarski, A., Gyurak, A., Debattista, C., Schatzberg, A. F., Sood, S., Day, C. V. A., Palmer, D. M., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.12.018 · Cited by 151
“They depart from findings that suggest escitalopram has a higher response rate than other SSRIs and SNRIs (Kennedy et al., 2009), or that venlafaxine produces higher response and remission rates than SSRIs (including sertraline and escitalopram) (Bauer et al.”
BackgroundImpact of antidepressants on cytokine production of depressed patients in Vitro
Munzer, A., Sack, U., Mergl, R., Schönherr, J., Petersein, C., Bartsch, S., Kirkby, K., Bauer, K., & Himmerich, H. (2013) · Toxins · doi:10.3390/toxins5112227 · Cited by 114
“Escitalopram compared to citalopram has been reported as having greater efficacy, fewer side effects, and greater cost-effectiveness due to higher relapse prevention and reduced hospital stay [31–36].”
BackgroundVerhoeven, J. E., Han, L. K. M., Lever-van Milligen, B. A., Hu, M. X., Révész, D., Hoogendoorn, A. W., Batelaan, N. M., van Schaik, D. J. F., van Balkom, A. J. L. M., van Oppen, P., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.064 · Cited by 112
Zhong, H., Haddjeri, N., & Sánchez, C. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2463-5 · Cited by 105
“Results of clinical trials and preclinical investigations indicate that escitalopram is more efficacious than citalopram and many other antidepressants (Kennedy et al. 2009; Montgomery et al. 2007; Sanchez et al. 2003, 2004; Wade et al. 2007).”
Does escitalopram reduce neurotoxicity in major depression?
Halaris, A., Myint, A.-M., Savant, V., Meresh, E., Lim, E., Guillemin, G., Hoppensteadt, D., Fareed, J., & Sinacore, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.026 · Cited by 86
Saragoussi, D., Touya, M., Haro, J. M., Jönsson, B., Knapp, M., Botrel, B., Florea, I., Loft, H., & Rive, B. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s136343 · Cited by 63
Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo
Baldwin, D. S., Asakura, S., Koyama, T., Hayano, T., Hagino, A., Reines, E., & Larsen, K. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.02.013 · Cited by 36
Comparative efficacy of escitalopram in the treatment of major depressive disorder
Lam, R., & Ali (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s12531 · Cited by 33
“The results are consistent with evidence from pooled analyses that the comparative effect sizes in favor of escitalopram increase with increasing baseline severity.(16,24,25) They are also consistent with those from head-to-head randomized controlled trials that prospectively enrolled patients with severe depression.”
MethodResultInfluentialPeselow, E. D., Tobia, G., Karamians, R., Pizano, D., & IsHak, W. W. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.022 · Cited by 19
“As significant differences in efficacy between the two have been reported (Kennedy et al., 2009; Ali and Lam, 2011), the addition of the relatively small number of citalopram patients could have affected the result of the larger escitalopram group.”
Background
Metadata
- Authors
- Kennedy, S. H., Andersen, H. F., & Thase, M. E.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2008-12-08
- Volume
- 25
- Issue
- 1
- Pages
- 161-175
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2129953844
- Cited by
- 140
- References
- 13
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.